Use of subcutaneous immunoglobulin in inflammatory myositis

Alan L Zhou¹, Nancy Maltez^{2

3}, Catherine Ivory^{2

3}

Affiliations

¹ Department of Medicine.
² Division of Rheumatology, Department of Medicine, University of Ottawa.
³ Clinical Epidemiology Program, The Ottawa Hospital Research Institute, Ottawa, Ontario, Canada.

Alan L Zhou et al. Rheumatol Adv Pract. 2021.

. 2021 Sep 6;5(3):rkab070.

doi: 10.1093/rap/rkab070. eCollection 2021.

Alan L Zhou¹, Nancy Maltez^{2

3}, Catherine Ivory^{2

3}

¹ Department of Medicine.
² Division of Rheumatology, Department of Medicine, University of Ottawa.
³ Clinical Epidemiology Program, The Ottawa Hospital Research Institute, Ottawa, Ontario, Canada.

No abstract available

References

1. Shabaninejad H, Asgharzadeh A, Rezaei N, Rezapoor A.. A comparative study of intravenous immunoglobulin and subcutaneous immunoglobulin in adult patients with primary immunodeficiency diseases: a systematic review and meta-analysis. Expert Rev Clin Immunol 2016;12:595–602. - PubMed
1. Nicolay U, Kiessling P, Berger M. et al. Health-related quality of life and treatment satisfaction in North American patients with primary immunedeficiency diseases receiving subcutaneous IgG self-infusions at home. J Clin Immunol 2006;26:65–72. - PubMed
1. Danieli MG, Gelardi C, Pedini V, Logullo F, Gabrielli A.. Subcutaneous IgG in the myositis spectrum disorders. Curr Rheumatol Rev 2018;14:194–9. - PubMed
1. Cherin P, Belizna C, Cartry O. et al. Long-term subcutaneous immunoglobulin use in inflammatory myopathies: a retrospective review of 19 cases. Autoimmun Rev 2016;15:281–6. - PubMed
1. Hachulla E, Benveniste O, Hamidou M. et al. High dose subcutaneous immunoglobulin for idiopathic inflammatory myopathies and dysimmune peripheral chronic neuropathies treatment: observational study of quality of life and tolerance. Int J Neurosci 2017;127:516–23. - PubMed